Top 50 Medical Startup Investors in United Kingdom

Investor	Medical United Kingdom investments
Parkwalk Advisors	25
UK Innovation & Science Seed Fund	21
Oxford Science Enterprises	19
Deepbridge Capital	18
Scottish Enterprise	18
SOSV	15
Oxford Science Enterprises	15
Oxford Technology Management	15
Archangels	14
Scottish Investment Bank	13
Mercia Fund Managers	13
Development Bank of Wales	12
GM&C Life Sciences Fund	12
AlbionVC	12
Newable Private Investing	11
Catapult Ventures	11
Oxford Capital	10
Cambridge Innovation Capital	10
M Ventures	9
Nesta Ventures	9
IP Group	9
Northstar Ventures	9
Jonathan Milner	9
Providence Investment Company Limited	8
Wellcome Trust	8
Praetura Ventures	7
Future Planet Capital	7
SyndicateRoom	7
Epidarex Capital	6
Business Growth Fund	6
Calculus Capital	6
Nina Capital	6
Tern	6
Foresight Group	6
Innovate UK	6
Crista Galli Ventures	6
Oxford Investment Consultants LLP	6
TRICAPITAL	5
Taiho Ventures	5
VentureFounders	5
SIS Ventures	5
Co-FundNI	5
Hoxton Ventures	5
Kelvin Capital	5
QUBIS	5
Woodford Investment Management	5
Syncona Partners LLP	5
Invest Northern Ireland	5
Angels 5K	5
Angels in MedCity	5

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Psyomics — Technology to support better mental health assessment - accelerating patients to the right care pathway, first time.
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Cambridge Electric Cement — Cambridge Electric Cement is a sustainable cement start-up. Its breakthrough process co-recycles steel and cement to produce a low carbon, circular cement product that offers very low emissions[1], circular, and scalable alternative to existing cement production.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Wave Photonics — Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Bristol, Bristol.
Vector Photonics — Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.
Presymptom Health — Presymptom Health is a pioneering medtech company that creates diagnostic tests to detect illnesses earlier to help save lives.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Finland

Portfolio highlights

Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

Circada — Innovative Circadian lighting reconnects the body clock with nature
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

Mirna — Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.
Aurora Avionics — Accelerating launch-vehicle development with flexible and modular avionics platforms.
Vector Photonics — Vector Photonics is a spin-out company from the University of Glasgow and is based in Glasgow, Scotland, one of the UK and world’s Optical and Photonics centres of excellence.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
OncoPrecision — We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity and Resistance Test, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access toPrecision Oncology and improve cancer patients' lives.
Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection
Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Speak with our Entrepreneurship Team, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee engagement surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

Hope Macy — Hope Macy is a dynamic and expanding financial technology company. Its primary focus is on consumers who require additional security in managing their money, as well as those in the subprime sector.
Validient — Onboard Clients With Confidence - Automated Compliance Software, AML and due diligence solutions. Empower your business.
Peppercorn — Peppercorn is an insurance company that engages in auto insurance and financial services. The company uses technology to create smarter customer service experiences that give more control to customers, starting with car insurance. Peppercorn uses cutting-edge conversational AI to change the whole car insurance experience.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

Mondra — AI-driven environmental insights platform that supports food system players to accelerate Scope 3 progress, reduce the cost of Net Zero, and drive competitive advantage.
Accelex — Accelex Technology, the technology solution to automate the acquisition, analysis and reporting of critical investment data. Learn more today.
OpenDialog AI — OpenDialog is the only conversational AI automation software to safely harness the most advanced Generative AI & LLMs in regulated sectors.

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

CroBio — Crobio presents an environmentally sustainable solution for reducing global water consumption and preventing agricultural drought.
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.
Pencil Biosciences — Next Generation Genome Editing Tool

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
Noggin HQ — The next generation of credit referencing is coming. Look busy.

Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United Kingdom, United States, Ireland

Portfolio highlights

Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .
Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
Outrun TX — Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.
Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.

We bring bold ideas to life to change the world for good.

Investment focus

Biotechnology, Medical Device, Medical
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
Radio Physics Solutions — Radio Physics Solutions is a security and investigation company that specializes in the fields of real-time concealed threat detection, Up to 30m Distance, autonomous, and unobtrusive. It specializes in providing early warning of threats concealed under peoples’ clothes, and so reduce the number of casualties caused by terrorists and criminalsglobally at schools, train stations, airports, government and military installations, tourist attractions and entertainment venues.Radio Physics Solutions was founded in 2009 and headquartered in Cambridgeshire, United Kingdom.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Therapeutics
Seed, Series A, Series B
United Kingdom, United States, Australia

Portfolio highlights

AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Northstar Ventures is a venture capital firm investing in innovative solutions to help solve the most pressing societal issues we have today. Our ticket sizes range from £100k to £500k into early stage tech companies. We provide added value in leveraging our network of university partners, funders, non-executive directors and talent to supporteach investment.

Investment focus

Software, E-Commerce, SaaS
Seed, Funding Round, Series A
United Kingdom, United States, Indonesia

Portfolio highlights

Lightox — Lightox has developed a unique range of molecular tools for use in imaging, therapeutics and assay development. These unique probes are smaller than any other commercially available fluorescent product. They offer the option of using our technologies as freely-moving probes that readily incorporate into cells or with a range of flexible linkers togive specificity to your unique applications and research needs.
DayaTani — DayaTani supplies farmers with comprehensive services to increase their productivity.
Circadacare — Circadacare helps elderly people and people with dementia live independently for longer with an integrated circadian lighting and home health monitoring system.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
Pencil Biosciences — Next Generation Genome Editing Tool
Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.

Providence Investment Company

Investment focus

Biotechnology, Biopharma, Medical
Funding Round, Series B, Seed
United Kingdom

Portfolio highlights

evonetix — Spearheading a radical new approach to gene synthesis to improve access to high-quality, gene-length DNA. Redefine possible.
DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Praetura Ventures has been supporting entrepreneurs with more than money since 2011. Click to find out more about how we can help businesses and investors.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
United Kingdom

Portfolio highlights

Lightox — Lightox has developed a unique range of molecular tools for use in imaging, therapeutics and assay development. These unique probes are smaller than any other commercially available fluorescent product. They offer the option of using our technologies as freely-moving probes that readily incorporate into cells or with a range of flexible linkers togive specificity to your unique applications and research needs.
Lunio — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
AccessPay — AccessPay develops and offers cloud-based payment and cash management solutions. The company’s cloud-based service provides ease of integration with any ERP, TMS, or other back-end systems. It also enables the straight-through processing of domestic and international payments via BACS, FPS, CHAPS, and SWIFT. By connecting an organization’s backoffice systems with its banks and providing a consolidated view of all banking relationships, AccessPay gives corporate enterprises real-time visibility of all cash balances and offers a detailed analysis, which helps financial professionals maximize the use of working capital. The company was founded in 2012 and is based in London, United Kingdom.

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Convertible Note
United Kingdom, United States, Singapore

Portfolio highlights

Captura — Captura mission is globally scalable carbon capture to support a sustainable future for the climate.
You. Smart. Thing. — Our travel demand management platform generates personalised low-carbon travel plans that enhance visitor experience & increase revenues.
Armada Technologies — Armada Technologies created the world's first Passive Air Lubrication technology. This award-winning technology operates in a passive mode and allows for discrete control of system output while completely decoupling system lubrication from ship speed. In doing so, PALS can provide appropriate boundary layer aeration under every operatingstate.

SyndicateRoom is fintech company made up of data-scientists, investment professionals, software developers and marketers with one mission: to be an early investor in every British startup success story.To do this – and make fund investors money – we don’t try to spot the next Big Thing.Instead, we apply a data-driven model to portfolioconstruction; a repeatable process designed to maximise returns and minimise risk for fund investors. As such, we build startup portfolios that don’t attempt to predict the future; they work to stack the odds in investors’ favour.Our fund, Access EIS, aims to build investors a diversified portfolio of 50+ companies by co‑investing exclusively with some of the UK’s best-performing angel investors.

Investment focus

Health Care, Software, Medical
Seed, Equity Crowdfunding, Funding Round
United Kingdom, United States, India

Portfolio highlights

Heatio — Heatio provides affordable renewable energy to homeowners.
Noggin HQ — The next generation of credit referencing is coming. Look busy.
Unibloom World — Unify targets with operational projects, make scenario simulations with cost impact in real time, compare new ideas, optimise actions and turn it into actionable projects with clear financial, regulations and business impact. Release burden from Sustainability Teams!

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.

Investment focus

Software, Information Technology, Health Care
Funding Round, Series A, Private Equity
United Kingdom, Ireland, United States

Portfolio highlights

Tevalis — Tevalis specialises in electronic point of sale systems in the hospitality, leisure and gaming sectors. Tevalis offers fully integrated EPOS hardware and software systems, designed to handle the demanding pressures of the hospitality industry.
Eventmaster — EventMaster is a ticketing platform. It also provides vital technology support to various national sports organizations.
NewGen — NewGen is a social-first creative and creator agency that stands at the intersection of culture, creators and community.

At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Seed
United Kingdom, United States, Ireland

Portfolio highlights

WorkL — WorkL provides all the resources you need in one location to find employment, advance your career, connect with others, and communicate.
Tagomics — Tagomics transform disease diagnosis through comprehensive multitopic profiling.
MIP Discovery — MIP Diagnostics develop and manufacture molecularly imprinted polymers (nanoMIPs) that act as synthetic alternatives to antibodies for IVD and other industries.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Software
Seed, Pre-Seed, Series A
United States, United Kingdom, Austria

Portfolio highlights

Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
Lillian Care — Lillian is building a nationwide network of health facilities in Germany.
Zetta Genomics — Zetta Genomics unleashes the power of genomic data to improve health outcomes for millions of patients around the world - and realise the potential of

Looking for an IoT investor for your start up or early stage company? Tern PLC is a venture capitalist working alongside ambitious entrepreneurs in the Internet of Things (IoT) space to deliver strategic IoT investment to grow your company.

Investment focus

Software, Information Technology, Artificial Intelligence
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Konektio — Optimize equipment performance and reduce downtime with AssetMinder's predictive maintenance and IoT solutions. Monitor energy usage and enhance operational efficiency seamlessly.
FundamentalVR — A strategic partner helping med-device leaders solve the Competency @ Scale Gap todrive commercial success.
Talking Medicines — Unlock the AI-Powered Conversational Data Intelligence for Healthcare Marketing Excellence Talking Medicines is transforming Healthcare Marketing by leveraging Advanced Data Science, Curated Large Language Models (LLMs), and Artificial Intelligence. Our mission is to unlock strategic intelligence within Healthcare Professional (HCPs) and Patient Conversational Data, providing actionable intelligence for Healthcare Marketing Agencies. Advanced-Data Science: Utilize cutting-edge data science techniques to analyze vast amounts of HCP and Patient Conversational Data, uncovering unseen intelligence that drive strategic decision-making. Curated Large Language Models: Implement expertly curated LLMs to accurately interpret and understand the difference in healthcare conversations for actionable Intelligence. Artificial Intelligence: Harness the power of AI to process and analyze Conversational Data, transforming raw information into strategic intelligence that enhances marketing efforts and ROI. Natural Language Interface: Delivers intelligence to customers through an intuitive natural language interface, making it easy to access and understand complex data. Just ask Drug-GPT what you want to know! At Talking Medicines, we are committed to revolutionizing Healthcare Marketing by providing our customers with the tools and intelligence they need to succeed in an increasingly complex and data-driven world.

Foresight Group is a listed infrastructure and private equity investment manager which has been managing funds on behalf of institutions and retail clients for more than 35 years. Foresight has over £7.2 billion of assets under management across a number of funds on behalf of some of the world’s largest institutional investors, family offices,private and high net-worth individuals and retail investors. Foresight's investment strategies are underpinned by a strong environmental, social & governance (“ESG”) focus, which increasingly meets the demands of today’s investors and ensures we are consistently working towards creating a sustainable legacy for future generations.

Investment focus

Software, Manufacturing, Health Care
Funding Round, Private Equity, Seed
United Kingdom, United States, Jersey

Portfolio highlights

Cavero Quantum — A quantum-safe symmetric cryptographic key solution built to last
Lepide — Combine identity and data security into a single solution for powerful data protection, threat detection/response, and compliance reporting.
Sprint Electric — Sprint Electric produces digital motor control solutions. Their product includes pl/x series, jl/x series, pl/xd series, open chassis-mount dc drives, and ancillary items. They offer customer support through email and phone contact.

Innovate UK is part of the UK Research and Innovation .

Investment focus

Health Care, Biotechnology, Software
Grant, Seed, Pre-Seed
United Kingdom, United States, Canada

Portfolio highlights

Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
AgriSound — Agri-tech company specialising in advanced sound analysis for monitoring insects.
Fuse Diagnostics — Fuse Diagnostics vision is to give lab quality diagnostic information wherever it is required through innovative, quick, low-cost testing.

Crista Galli Ventures invests in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.

Investment focus

Health Care, Wellness, Medical
Seed, Pre-Seed, Series A
United Kingdom, United States, Sweden

Portfolio highlights

Jude — Hey, we're Jude. A healthcare start-up on a mission is to bring bladder care into the mainstream.
Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
Collective Minds Radiology — Collective Minds® is the new radiology workspace. A cloud-based service for collaboration, consultation and access to new digital tools and expertise. We are building the largest global network of collective and artificial intelligence, with humans and machines.

xford Investment Consultants LLP ("OIC") advises Thompson Taraz, the Investment Manager of Oxford Technology and Innovations EIS Fund ("OTIF"). OIC is an Appointed Representative of Stoneware Captial LLP, which is authorized and regulated by the Financial Conduct Authority in the United Kingdom.The focus of OIC research ison University of Oxford spin out companies.Over the last fifteen years Oxford has produced a string of world-class spin-out companies. It is our belief that the next generation of world-class Oxford businesses is just waiting to be discovered.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Funding Round
United Kingdom

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Caristo Diagnostics — Our AI powered CaRi-Heart technology uncovers coronary inflammation, atherosclerosis, and plaque progression on cardiac CT. Learn more about our award-winning technology
Oxford Quantum Circuits — We deliver Enterprise ready quantum solutions that are hybrid workload ready

The TRICAPITAL Syndicate is a business angel cohort of entrepreneurs, CEOs and business leaders who have founded, funded and built companies

Investment focus

Biotechnology, Software, Health Care
Funding Round, Seed, Series B
United Kingdom, France

Portfolio highlights

ŌGI Bio — Offering an affordable route to automating routine microbial culturing with a unique, modular, retrofittable device
Sellmyartworks — SellmyArtworks is to buy and sell pre-loved artwork in a simple, fast, and affordable way like no other pre-owned art seller.
Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality

Taiho Ventures is a company that specializes in the research and development of pharmaceuticals.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
hC Bioscience — hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
Storm Therapeutics — Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Volution is a UK based Venture Capital firm. We back ambitious Fintech and SaaS businesses, ready to accelerate their growth to Series B and beyond.

Investment focus

Health Care, Software, Medical
Series A, Funding Round, Seed
United Kingdom, United States

Portfolio highlights

Zopa — Zopa is a P2P money lending service that allows lenders and borrowers to deal directly with one another, cutting out the banks who act as middlemen. It works in the following way: the company first categorizes borrower credit grades with an A*, A, B, C, or Y rating; then lenders make offers that vary by money amount and time period for persons witha certain credit grade, and borrowers can then agree the aggregate offered rate.Zopa takes on such responsibilities as distributing money between parties, completing the legal paperwork, performing borrower identity/credit checks, and employing a collections agency that chases missed payments for the lender.Zopa also mitigates risk for lenders by enforcing monthly direct debit repayment, making borrowers sign a legal contract, and allowing lenders to lend small chunks of money to individual borrowers (i.e. someone lending Â£1000 would have their money spread across say, 100 borrowers).The company itself makes money by charging a fixed fee for borrowers and a 1% annual fee for lenders.Zopa has received public acclaim as well, having been awarded CNET Technology Awards' 2006 Internet Innovation of the Year, the 2007 Webby Award for Best Banking/Bill-Paying Website, the 2008 Webby Award for Financial Services, the Banker 2007 Award for Best Internet Project, and Moneywise 2009 Awards for Best Customer Service and Best Personal Loan.One of the three initial members of the UK's Peer-to-Peer Finance Association, together with FundingCircle and RateSetter. Other P2P lending services include
DeadHappy — DeadHappy is an insurtech company that provides digital pay-as-you-go life insurance services. It specializes in offering flexible life insurance policies that are designed to be cheaper, easier, and better than existing traditional providers. Its offerings include pricing insurance based on current circumstances and the option to add furthercoverage on a rolling basis.The company was founded in 2013 and is headquartered in Leicester, England.
Lightpoint Medical — Lightpoint is developing miniaturized imaging and sensing tools for advanced robot-assisted cancer surgery.

SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

Nebu~Flow — Nebu~Flow develops the next generation of nebulisers to enable the delivery of life changing treatments.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
Nami Surgical — Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments.

Through Co-Fund NI £12.5million will be made available to invest alongside business angels and business angel syndicates (hereafter referred to as "private investors" or "syndicates") into eligible SME's based in Northern Ireland. When matched 45% public with 55% private investors on a deal-by-deal basis this will give anoverall "fund" size of £28m.This initiative is provided by Invest Northern Ireland and part-financed by the European Regional Development Fund under the Invest for Growth and Jobs Programme 2014-2020.

Investment focus

Software, Health Care, Information Technology
Seed, Funding Round, Pre-Seed
United Kingdom, Ireland

Portfolio highlights

Kinsetsu — Kinsetsu provides intelligent tracking solutions to help organisations automate and optimise tasks and services.
CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

Investment focus

Artificial Intelligence, Information Technology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

Cogna — Cogna offers an AI-powered SaaS platform that streamlines the integration of data across several business domains.
CuspAI — CuspAI is a revolutionary AI startup that is developing a platform for next-generation materials to address global sustainability and renewable energy concerns. CuspAI uses cutting-edge generative AI, deep learning, and molecular simulation to accelerate the material design process. Their platform works similarly to a search engine for materials,allowing users to request certain properties for new materials on demand.
Malted AI — Malted AI is a developer of a low-code platform enables enterprises to build and deploy large language models-enabled applications at scale, using distillation to inject domain-specific knowledge into smaller, focused models, trained on proprietary data in a secure environment.

We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors

Investment focus

Health Care, Biotechnology, Manufacturing
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

novosound — Novosound is an award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.
Snappy Shopper — Order your favourite products from your local convenience store, for delivery from as little as 30 minutes with Snappy Shopper. Your every day essentials are only a click away - order your grocery delivery online or through our app.
Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.

QUBIS Ltd was established in 1984 by The Queen's University of Belfast to commercialise the University's research and development activities through the formation of 'spin-out' businesses. Qubis Ltd is an investment vehicle, holding company which takes an equity holding in a new spin-out venture in return for an investment ofcash and/or Intellectual Property. Qubis Ltd 'pulls through' appropriate R & D from the laboratory into the commercial market place.

Investment focus

Health Care, Medical, Biotechnology
Seed, Funding Round, Pre-Seed
United Kingdom, United States

Portfolio highlights

VascVersa — VascVersa is a new cell therapy company based in Northern Ireland. At VascVersa we are developing medicines to create new blood vessels, repair tissue and promote healing.
CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Woodford Investment Management is a privately owned investment firm manages equity mutual funds. At Woodford, they don’t want to be just another fund management company. They want to create something different and better for their investors and they feel strongly that existing and potential clients are entitled to understand what they are doingwith their money.As investors, they are active, engaged, long-term, disciplined, diligent and focused. That’s a lot of things to say about their selves but each word is important in helping you to understand how they manage money – they will explain in more detail as they move along.Their investment approach and process are focused on value discovery, not price discovery. They believe that financial markets are inherently inefficient and that, through disciplined and diligent analysis, they can identify investment opportunities where market prices do not reflect long-term fundamental value. By exploiting this pervasive market characteristic, they believe they can create real long-term value for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United Kingdom, United States, Ireland

Portfolio highlights

Inivata — Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collectedthrough a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
Revolut — Join 40+ million customers globally using Revolut to send money to 160+ countries, hold up-to 36 currencies in app, spend in 150+ currencies, and manage their money.
Atom Bank — Savings accounts, a range of mortgages & business loans, you'll find it all with Atom bank. App-based and designed to be hassle-free. Download the app today.

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Therapeutics, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

Spur Therapeutics — Spur Therapeutics is a clinical-stage biotechnology business dedicated to creating life-changing medicines for crippling chronic illnesses.
SwanBio Therapeutics — SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.
Yellowstone Biosciences — Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted, With the potential to dramatically improve patient outcomes.

Invest Northern Ireland is Northern Ireland's economic development agency. Their overall goal is to help create wealth for the benefit of the whole community by strengthening the economy and helping it grow.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Grant, Seed
United Kingdom, United States, Ireland

Portfolio highlights

TruCorp — TruCorp: Your source for lifelike Medical Training Equipment. Explore our intubation manikins & airway trainers. Request a free demo today!
Signum Surgical — Founded in 2014 by Eoin Bambury and Moshe Zilversmit, Signum Surgical is a medtech platform striving to develop technology that could cure perianal fistula. Bambury and Zilversmit, who met on the BioInnovate Ireland programme at NUI Galway, recognised a lack of innovation surrounding the treatment of perianal fistulas (small tunnels that developbetween the end of the bowel and the skin near the anus). The device developed by Signum Surgical is implanted post-surgery to prevent reinfection and to allow a faster healing process.
CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.

Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.

Investment focus

Biotechnology, Software, Medical
Seed, Funding Round, Angel
United Kingdom

Portfolio highlights

Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
Novastone Media — With its unique asymmetric technology, novastone puts you directly where your clients want to talk to you.
Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.

Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Angel
United Kingdom, United States

Portfolio highlights

Atelerix — Discover Atelerix's hypothermic hydrogels for eco-friendly, reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples today.
Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.